A Phase 1, Randomized, Placebo-controlled, Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP5094 Following Multiple Intravenous Doses in Subjects With Rheumatoid Arthritis on Methotrexate
Phase of Trial: Phase I
Latest Information Update: 07 Oct 2017
At a glance
- Drugs ASP 5094 (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Astellas Pharma
- 03 Oct 2017 Status changed from active, no longer recruiting to completed.
- 12 Dec 2016 Status changed from recruiting to active, no longer recruiting.
- 08 Mar 2016 New trial record